Understanding Tardive Dyskinesia
Tardive dyskinesia is a neurological disorder that is often caused by long-term use of certain medications, particularly antipsychotic drugs. It is characterized by repetitive and involuntary movements of the face, tongue, lips, and other parts of the body. These movements can be disruptive and affect a person's ability to perform daily activities. Tardive dyskinesia can occur after months or years of taking antipsychotic medication, and its exact cause is not well understood. However, it is believed to be related to the way medications affect the dopamine receptors in the brain.
Introduction to Valbenazine
Valbenazine is a medication that belongs to a class of drugs known as vesicular monoamine transporter 2 (VMAT2) inhibitors. It is approved by the U.S. Food and Drug Administration (FDA) for the treatment of tardive dyskinesia in adults. Valbenazine works by reducing the amount of dopamine released in certain areas of the brain, which helps to control the involuntary movements associated with tardive dyskinesia.
The Connection between Valbenazine and Tardive Dyskinesia
Valbenazine is specifically designed to target the symptoms of tardive dyskinesia. By inhibiting the VMAT2 transporter, valbenazine decreases the release of dopamine in the brain. This reduction in dopamine helps to regulate the abnormal movements seen in tardive dyskinesia. The exact mechanism of how valbenazine works is not fully understood, but it is believed to act by modulating the dopamine signaling pathways in the brain. Clinical studies have shown that valbenazine significantly reduces the severity of tardive dyskinesia symptoms compared to a placebo. It has also been found to improve patients' quality of life by reducing the impact of involuntary movements on daily activities.
Side Effects and Considerations
Like any medication, valbenazine may cause side effects in some individuals. Common side effects include sleepiness, dry mouth, and nausea. It is important for patients to discuss any concerns or potential interactions with their healthcare provider before starting valbenazine. Valbenazine is not recommended for use in individuals with severe liver impairment. It is also important to follow the prescribed dosage and report any new or worsening symptoms to the healthcare provider.